Linking microRNAs with cells that regulate the immune system could lead to new disease therapies

Linking genetic material microRNAs with cells that regulate the immune system could one day lead to new therapies for treating cancer, infections and autoimmune diseases, according to a Henry Ford Hospital study.

Qing-Sheng Mi, M.D., Ph.D., the study's senior author and director of Henry Ford's Immunology Program, says their findings are important because it shows for the first time an association between microRNAs and a key subset of immune regulatory cells in the body, natural killer T cells (NKT), which are known to lead to autoimmune diseases and cancer.

The study is being published June 1 in the Proceedings of the National Academy of Sciences.

"While further studies are needed, we believe this provides important insight about how microRNAs can regulate NKT cells, and signals a major step forward in biology science for looking at new therapies for treating some chronic immune disease," Dr. Mi says.

MicroRNAs are short strands of genetic material that researchers believe perform a vital role in healthy development by turning off gene activity. NKT cells potent regulators of diverse immune responses in the body.

By genetically modifying mice with specific deletion microRNAs in hematopoietic stem cells, Henry Ford researchers showed that the lack of microRNAs can block the development and function of normal NKT cells.

If researchers are successful at identifying unique microRNA that specifically regulate NKT cells, Dr. Mi, it could lead to new treatment therapies for some chronic disease.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into stiff-person syndrome, advancing diagnosis and treatment